糖尿病性胃不全麻痺治療の世界市場

糖尿病性胃不全麻痺治療の世界市場は2030年までに27億米ドルに到達

2024年に23億米ドルと推定される糖尿病性胃不全麻痺治療の世界市場は、2024年から2030年にかけてCAGR 2.6%で成長し、2030年には27億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである医薬品は、CAGR 3.3%を記録し、分析期間終了時には17億米ドルに達すると予想されます。外科治療製品セグメントの成長率は、分析期間中CAGR 1.6％と推定されます。

米国市場は6億2,220万米ドルと推定、中国はCAGR5.2％で成長予測

米国の糖尿病性胃不全麻痺治療市場は、2024年には6億2,220万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを5.2%として、2030年までに5億1,970万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.1％と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界の糖尿病性胃不全麻痺治療市場- 主要動向と促進要因のまとめ

治療イノベーションは未診断疾患に追いつくか？

糖尿病性胃不全麻痺（長期糖尿病による慢性的な胃運動障害）は、糖尿病の合併症の中でも最も診断が遅れ、治療が困難な疾患の一つです。糖尿病性胃不全麻痺は、主に1型糖尿病および長期にわたる2型糖尿病に罹患し、胃排出遅延、悪心、嘔吐、腹部膨満感、血糖コントロール障害を引き起こします。現在、世界の糖尿病性胃不全麻痺治療市場は、疾患に対する認識の高まり、診断の改善、新規のプロキネティック療法の導入などにより、変革の時期を迎えています。

最も重要な動向の一つは、対症療法から標的運動機能調節薬への移行です。これまでは食事療法、制吐剤、適応外の運動促進剤の使用で対処してきたが、現在では選択的セロトニン受容体作動薬、グレリン受容体作動薬、CGRP拮抗薬に焦点を当てた医薬品の研究開発が復活しつつあります。これらの技術革新は、単に症状を抑えるのではなく、胃運動障害の根本的な病態生理学に対処することを目的としています。

研究開発は胃不全麻痺の治療状況をどのように再構築しているのか？

従来の治療法では、長い間メトクロプラミド、ドンペリドン、エリスロマイシン、オンダンセトロンに頼ってきました。しかし、これらの薬剤は、錐体外路症状、QT延長、頻脈などの副作用により、長期間の使用が制限されています。これに対し、製薬会社はより標的を絞り、より忍容性の高いプロキネティック薬の開発を進めています。有望な候補としては、胃排出を促進し、中枢神経系の副作用が少なく症状の重症度を軽減する可能性を示すグレリン受容体作動薬であるrelamorelinがあります。

その他の臨床試験中の薬剤としては、velusetrag（5-HT4アゴニスト）やcamicinalがあり、いずれも心血管系や神経系のリスクを伴わずに消化管運動を選択的に刺激するように設計されています。さらに、幽門括約筋へのボツリヌス毒素注射や胃電気刺激も、難治性の症例に対するインターベンションの選択肢として検討されています。これらの進歩により、特に症状が重く胃シンチグラフィで胃排出遅延が確認された患者に対しては、個別化されたメカニズムに基づく治療法へと焦点が移りつつあります。

需要はどこで生まれ、誰が主な利害関係者か？

糖尿病性胃不全麻痺治療市場は、糖尿病有病率の高い地域、特に北米、西欧、中国、インドに集中しています。米国は、運動機能検査や専門的な消化器内科サービスへのアクセスが良いため、診断率と治療普及率の両面で市場をリードしています。しかし、症状が他の消化器疾患と重複していることが多く、標準化された評価プロトコールがないため、診断不足が世界的に大きな障害となっています。

内分泌病専門医、消化器病専門医、糖尿病専門医は重要な処方者であり、治療の決定には学際的な連携が必要となることが多いです。重篤な症例の診断と管理には、大学病院や三次紹介病院が重要な役割を果たす一方、製薬企業はこれらの機関と密接に連携して臨床試験を実施し、治療適応を拡大しています。さらに、糖尿病患者支援団体や遠隔医療プラットフォームが症状の早期発見に貢献し、治療へのアクセスとアドヒアランスを向上させています。

糖尿病性胃不全麻痺治療市場の成長を牽引しているのは？

糖尿病性胃不全麻痺治療市場の成長は、糖尿病の罹患率、アンメット・クリニカル・ニーズ、新たな薬理学的ソリューションに関連するいくつかの要因によって牽引されています。糖尿病の世界の増加（特に若年層と高齢化）により、胃不全麻痺の潜在的な患者層が著しく拡大しており、特に管理が不十分な症例やインスリン依存の症例で顕著です。胃運動機能診断薬に対する認識と入手可能性の向上も、他の消化器疾患との鑑別と検出を向上させています。

医薬品の技術革新は主要な促進要因であり、新しいクラスのプロキネティクスや症状をターゲットにした治療薬が後期臨床段階に入りつつあります。これらの薬剤は忍容性と有効性が改善されており、以前は適応外の副作用の出やすい治療が主流であったこの分野で、より安全な長期的解決策と位置づけられています。さらに、診断検査や専門的な診察に対する医療保険の適用範囲が改善されたことも、先進国での市場浸透を後押ししています。

遠隔症状追跡アプリ、ウェアラブル血糖モニター、AI支援食事管理プラットフォームなど、デジタルヘルスツールの融合も、より個別化された治療計画を促進しています。こうした技術統合は、的を絞った教育キャンペーンや臨床試験の拡大とともに、世界のヘルスケアシステム全体における糖尿病性胃不全麻痺の理解、管理、収益化の方法を再構築しています。

セグメント

製品タイプ（医薬品、外科的治療製品）;疾患適応（代償性胃不全症、胃不全）;販売チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の41社）

• Abbott Laboratories
• AbbVie Inc.
• Alfa Wassermann S.p.A.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bayer AG
• Boston Scientific Corporation
• C. R. Bard, Inc.（BD）
• Cardinal Health, Inc.
• Cipla Limited
• Evoke Pharma, Inc.
• GlaxoSmithKline plc
• Janssen Global Services, LLC
• Medtronic plc
• Neurogastrx, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Vanda Pharmaceuticals, Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Diabetic Gastroparesis Treatment Market to Reach US$2.7 Billion by 2030

The global market for Diabetic Gastroparesis Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Surgical Treatment Products segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$622.2 Million While China is Forecast to Grow at 5.2% CAGR

The Diabetic Gastroparesis Treatment market in the U.S. is estimated at US$622.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$519.7 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Diabetic Gastroparesis Treatment Market - Key Trends & Drivers Summarized

Is Therapeutic Innovation Catching Up With an Underdiagnosed Condition?

Diabetic gastroparesis-a chronic gastric motility disorder caused by long-term diabetes-remains one of the most underdiagnosed and difficult-to-treat complications of diabetes. It primarily affects individuals with Type 1 and long-standing Type 2 diabetes, leading to delayed gastric emptying, nausea, vomiting, bloating, and impaired glycemic control. The global diabetic gastroparesis treatment market is now undergoing a transformation, driven by growing disease awareness, diagnostic improvements, and the introduction of novel prokinetic therapies.

One of the most significant trends is the transition from symptomatic treatment to targeted motility-modulating agents. Historically managed with dietary modifications, antiemetics, and off-label use of prokinetics, the market is now witnessing a resurgence in pharmaceutical R&D focused on selective serotonin receptor agonists, ghrelin receptor agonists, and CGRP antagonists. These innovations aim to address the underlying pathophysiology of impaired gastric motility rather than merely suppress symptoms.

How Is R&D Reshaping the Therapeutic Landscape for Gastroparesis?

Traditional treatment approaches have long relied on metoclopramide, domperidone, erythromycin, and ondansetron. However, their long-term use is limited by adverse effects such as extrapyramidal symptoms, QT prolongation, and tachyphylaxis. In response, pharmaceutical companies are developing more targeted, better-tolerated prokinetic agents. Promising candidates include relamorelin, a ghrelin receptor agonist that enhances gastric emptying and shows potential in reducing symptom severity with fewer CNS side effects.

Other drugs in clinical trials include velusetrag (5-HT4 agonist) and camicinal, both designed to selectively stimulate gastrointestinal motility without cardiovascular or neurological risks. Additionally, botulinum toxin injections into the pyloric sphincter and gastric electrical stimulation are being explored as interventional options for refractory cases. These advancements are shifting the focus toward personalized, mechanism-based therapies, particularly for patients with severe symptoms and delayed gastric emptying confirmed by gastric scintigraphy.

Where Is Demand Emerging and Who Are the Primary Stakeholders?

The diabetic gastroparesis treatment market is concentrated in regions with high diabetes prevalence-particularly in North America, Western Europe, China, and India. The U.S. leads the market in terms of both diagnosis rates and treatment adoption due to greater access to motility testing and specialized gastroenterology services. However, underdiagnosis remains a major hurdle globally, as symptoms often overlap with other gastrointestinal conditions and lack standardized evaluation protocols.

Endocrinologists, gastroenterologists, and diabetologists are key prescribers, with treatment decisions often requiring multidisciplinary coordination. Academic medical centers and tertiary referral hospitals play a crucial role in diagnosing and managing severe cases, while pharmaceutical companies are working closely with these institutions to conduct clinical trials and expand therapeutic indications. Moreover, diabetic patient advocacy groups and telemedicine platforms are contributing to earlier recognition of symptoms, thereby improving treatment access and adherence.

What’s Driving Growth in the Diabetic Gastroparesis Treatment Market?

The growth in the diabetic gastroparesis treatment market is driven by several factors tied to diabetes incidence, unmet clinical need, and emerging pharmacological solutions. The global rise in diabetes-particularly in younger adults and the aging population-has significantly expanded the potential patient pool for gastroparesis, especially in poorly managed or insulin-dependent cases. Increasing awareness and availability of gastric motility diagnostics are also improving detection and differentiation from other GI disorders.

Pharmaceutical innovation is a key growth driver, with new classes of prokinetics and symptom-targeted therapies entering late-stage clinical development. These agents offer improved tolerability and efficacy, positioning them as safer long-term solutions in a field previously dominated by off-label and side-effect-prone treatments. Additionally, improvements in health insurance coverage for diagnostic tests and specialty consultations are aiding market penetration in developed countries.

The convergence of digital health tools-including remote symptom tracking apps, wearable glycemic monitors, and AI-assisted dietary management platforms-is also fostering more individualized treatment plans. These technological integrations, along with targeted education campaigns and expanding clinical trials, are reshaping how diabetic gastroparesis is understood, managed, and monetized across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Diabetic Gastroparesis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Drugs, Surgical Treatment Products); Disease Indication (Compensated Gastroparesis, Gastric Failure); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Alfa Wassermann S.p.A.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bayer AG
• Boston Scientific Corporation
• C. R. Bard, Inc. (BD)
• Cardinal Health, Inc.
• Cipla Limited
• Evoke Pharma, Inc.
• GlaxoSmithKline plc
• Janssen Global Services, LLC
• Medtronic plc
• Neurogastrx, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Vanda Pharmaceuticals, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Diabetic Gastroparesis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Prevalence of Type 1 and Type 2 Diabetes Propels Demand for Gastroparesis Therapies
  • Increased Awareness and Diagnosis Rates Throw the Spotlight on Unmet Clinical Needs in Gastroparesis Management
  • Launch of Novel Prokinetic Agents Strengthens Business Case for Pharmacological Intervention
  • Advancements in Gastric Electrical Stimulation Devices Accelerate Innovation in Non-Pharmacological Treatments
  • Regulatory Approvals for New Drug Classes Drive Competitive Landscape in Diabetic Gastroparesis Treatment
  • Patient-Centric Care Models Propel Growth in Personalized Gastroparesis Treatment Strategies
  • Rising Healthcare Expenditure in Emerging Markets Expands Access to Advanced Therapeutics
  • Growing Pipeline of Promotility Agents Spurs Market Interest Among Biopharma Investors
  • Post-Pandemic Focus on Gastrointestinal Complications in Diabetics Drives Disease Monitoring and Therapy Uptake
  • Clinical Research Linking Gastroparesis to Poor Glycemic Control Highlights Need for Targeted Treatment
  • Integration of Digital Health Monitoring Tools Enhances Early Detection and Treatment Adherence
  • Increased Hospitalization Due to Gastroparesis Complications Generates Urgency for Effective Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Diabetic Gastroparesis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Surgical Treatment Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Surgical Treatment Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Surgical Treatment Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Compensated Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Compensated Gastroparesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Compensated Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gastric Failure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Gastric Failure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Italy 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 101: UK Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: UK 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Spain 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 119: Russia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Russia Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Russia 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 149: Australia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Australia Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Australia 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 158: India Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: India Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: India 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 161: India Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 167: South Korea Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: South Korea Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: South Korea 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 185: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Latin America Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 197: Argentina Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Argentina Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Argentina 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Brazil 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 215: Mexico Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Mexico Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Mexico 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 233: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 234: Middle East Historic Review for Diabetic Gastroparesis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 245: Iran Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Iran Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Iran 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Israel 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Saudi Arabia Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Saudi Arabia 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 272: UAE Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: UAE Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: UAE 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Rest of Middle East Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Rest of Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Diabetic Gastroparesis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 290: Africa Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Africa Historic Review for Diabetic Gastroparesis Treatment by Product Type - Drugs and Surgical Treatment Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Africa 15-Year Perspective for Diabetic Gastroparesis Treatment by Product Type - Percentage Breakdown of Value Sales for Drugs and Surgical Treatment Products for the Years 2015, 2025 & 2030
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Diabetic Gastroparesis Treatment by Disease Indication - Compensated Gastroparesis and Gastric Failure Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Diabetic Gastroparesis Treatment by Disease Indication - Percentage Breakdown of Value Sales for Compensated Gastroparesis and Gastric Failure for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Diabetic Gastroparesis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Diabetic Gastroparesis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION